Novo Nordisk A/S (TSX:NOVO)
18.38
+0.73 (4.14%)
Nov 13, 2026, 4:00 PM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 79.20B DKK in the quarter ending September 30, 2026, with 5.63% growth. This brings the company's total for the last twelve months to 333.65B, up 5.72% year-over-year. In the year 2025, Novo Nordisk had annual revenue of 309.06B with 6.43% growth.
Revenue (ttm)
333.65B DKK
Revenue Growth
+5.72%
P/S Ratio
3.59
Revenue / Employee
5.00M DKK
Employees
66,700
Market Cap
258.31B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Novo Nordisk breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 309.06B | 18.66B | 6.43% |
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.21B |
| Extendicare | 2.17B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| WELL Health Technologies | 1.56B |
| Sienna Senior Living | 1.11B |
| Vireo Growth | 611.54M |
| Knight Therapeutics | 563.45M |
Novo Nordisk News
- 11 minutes ago - Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval - WSJ
- 13 hours ago - Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027 - The Motley Fool
- 22 hours ago - Novo Nordisk announces results from two post hoc analyses of phase 3 Redefine 1 - TheFly
- 22 hours ago - Novo Nordisk presents findings on reduction in food noise when using Wegovy - TheFly
- 22 hours ago - Novo Nordisk announces primary results from Phase 3 Redefine 9 trial - TheFly
- 1 day ago - Novo Nordisk Says Wegovy May Help Reduce 'Food Noise' In Adults With Obesity - Nasdaq
- 1 day ago - Novo Nordisk Reports Strong Weight-Loss Results In Phase 3 REDEFINE 9 Trial Of CagriSema - Nasdaq
- 1 day ago - Weight-loss pill helps patients lose 6% of body weight in three months: data - BNN Bloomberg